Abstract

ObjectiveTo investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors (TNFi) or abatacept.MethodsUsing claims data...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Infections in Children Treated With Biological Agents
Andreas Woerner ... Nicole Ritz
Pediatric Infectious Disease Journal | VOL. 32
Andreas Woerner, et. al.Andreas Woerner ... Nicole Ritz
01 Mar 2013
Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.
Leslie Briars ... Todd A Lee
Rheumatology (Oxford, England) | VOL. 57
Leslie Briars, et. al.Leslie Briars ... Todd A Lee
18 Apr 2017
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
Jeroan J Allison ... Michael Saag
Arthritis & Rheumatism | VOL. 56
Jeroan J Allison, et. al.Jeroan J Allison ... Michael Saag
28 Mar 2007
OP0324 Risk of serious infections in rheumatoid arthritis patients treated with abatacept, rituximab and tocilizumab in denmark and sweden
J Askling ... M Heltand
Annals of the Rheumatic Diseases | VOL. 77
J Askling, et. al.J Askling ... M Heltand
01 Jun 2018
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers